1. Biocon-Pfizer: The $350 million insulin deal that wasn’t
In March 2012, Biocon and Pfizer ‘amicably’ parted ways after their 15-month-old $350 million deal to market Biocon’s insulin products fell through. Both partners were hit hard: Pfizer lost $100 million in upfront payment, a significant part of the $100 million escrow amount and a small severance fee; for Biocon, the split restricted scope of monetising its insulin biosimilars in the US and Europe. The official reason for the break-up was a shift in priorities at Pfizer, which wanted to focus on its core strengths—diabetes, and its therapeutics not being part of them.
That’s a little difficult to believe, as priorities at big pharma don’t change at such short notice. But Biocon took it in its stride. In November, it found a partner in Bristol-Myers Squibb for its oral insulin programme (not part of the Pfizer pact).
(This story appears in the 11 January, 2013 issue of Forbes India. To visit our Archives, click here.)